Stock ALMIRALL SA
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Almirall SA CBOE EUROPE EQUITIES

Equities

ES0157097017

Real-time Estimate Tradegate
Other stock markets
 03:01:59 2024-06-17 am EDT
9.825 EUR 0.00% Intraday chart for Almirall SA
Jun. 10 Almirall: extension of indication in actinic keratosis CF
Jun. 10 Almirall’s Skin Disease Drug Gets US FDA Nod for Larger Treatment Area MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm2
BU
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
BU
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
BU
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
BU
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
BU
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
BU
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
BU
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
BU
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
BU
Almirall’s Nine-month 2023 Results
BU
Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years
BU
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
BU
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis
BU
Centrient Pharmaceuticals joins Almirall’s growing innovation hub in Barcelona
BU
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
BU
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
BU
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
BU
Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing
BU
Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase
BU
Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALM Stock
  4. Stock
  5. News Almirall SA
  6. Press Releases